MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 9.5% – Should You Sell?

Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) traded down 9.5% on Thursday . The company traded as low as $1.33 and last traded at $1.33. 1,003,093 shares were traded during mid-day trading, an increase of 64% from the average session volume of 610,815 shares. The stock had previously closed at $1.47.

MAIA Biotechnology Price Performance

The firm has a 50-day simple moving average of $1.36 and a 200-day simple moving average of $1.57. The firm has a market capitalization of $80.86 million, a PE ratio of -1.99 and a beta of 0.22.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.04. Equities analysts expect that MAIA Biotechnology, Inc. will post -0.52 earnings per share for the current year.

Insider Activity at MAIA Biotechnology

In other MAIA Biotechnology news, Director Stan Smith purchased 75,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were acquired at an average price of $1.34 per share, for a total transaction of $100,500.00. Following the purchase, the director directly owned 1,519,178 shares of the company’s stock, valued at $2,035,698.52. The trade was a 5.19% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vlad Vitoc purchased 72,700 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were acquired at an average price of $1.39 per share, for a total transaction of $101,053.00. Following the purchase, the chief executive officer directly owned 976,121 shares in the company, valued at approximately $1,356,808.19. The trade was a 8.05% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 149,700 shares of company stock valued at $204,233 over the last 90 days. 19.81% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On MAIA Biotechnology

A number of institutional investors have recently bought and sold shares of MAIA. Corsair Capital Management L.P. bought a new stake in MAIA Biotechnology during the first quarter valued at about $140,000. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology in the fourth quarter worth about $120,000. PVG Asset Management Corp bought a new position in shares of MAIA Biotechnology in the first quarter worth about $46,000. Geode Capital Management LLC raised its stake in shares of MAIA Biotechnology by 9.5% in the fourth quarter. Geode Capital Management LLC now owns 296,740 shares of the company’s stock worth $454,000 after buying an additional 25,684 shares during the period. Finally, Ritholtz Wealth Management purchased a new position in shares of MAIA Biotechnology during the 4th quarter valued at about $35,000. 5.65% of the stock is owned by institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.